RU95100238A - Method of treatment of mamma cancer - Google Patents

Method of treatment of mamma cancer

Info

Publication number
RU95100238A
RU95100238A RU95100238/14A RU95100238A RU95100238A RU 95100238 A RU95100238 A RU 95100238A RU 95100238/14 A RU95100238/14 A RU 95100238/14A RU 95100238 A RU95100238 A RU 95100238A RU 95100238 A RU95100238 A RU 95100238A
Authority
RU
Russia
Prior art keywords
treatment
day
complications
relapses
prescribed
Prior art date
Application number
RU95100238/14A
Other languages
Russian (ru)
Other versions
RU2071771C1 (en
Inventor
В.А. Шматко
Original Assignee
В.А. Шматко
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by В.А. Шматко filed Critical В.А. Шматко
Priority to RU95100238A priority Critical patent/RU2071771C1/en
Application granted granted Critical
Publication of RU2071771C1 publication Critical patent/RU2071771C1/en
Publication of RU95100238A publication Critical patent/RU95100238A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FIELD: medicine, oncology. SUBSTANCE: method involves preliminary estimation of patient sensitivity to cyclic adenosine-3',5'-monophosphate sodium salt. This preparation is prescribed to sensitive patients at concentration 3 x 10M by sublingual route, three times per 24 h, every other day, by 15-20 drops, 30 min before eating for 30 days. Method can be used for treatment of mamma cancer of III-IV stages. EFFECT: enhanced effectiveness of treatment, decreased complications and relapses.

Claims (1)

Изобретение относится к медицине и может применяться для лечения рака молочной железы III- IY стадии. Цель изобретения: снижение осложнений и повышение эффективности лечения. Для этого больной предварительно определяют чувствительность к натриевой соли циклического аденозин-3',5'-монофосфата и при наличии таковой назначают препарат концентрацией 3•10- 5М сублигвально три раза в сутки через день по 15 - 20 капель за полчаса до еды, курс лечения 30 дней. Изобретение позволяет повысить сроки выживаемости тяжелых больных, снизить число осложнений и рецидивов.The invention relates to medicine and can be used to treat stage III-IY breast cancer. The purpose of the invention: reducing complications and increasing the effectiveness of treatment. For this, the patient is preliminarily determined by sensitivity to the sodium salt of cyclic adenosine-3 ', 5'-monophosphate and, if there is one, a drug is prescribed with a concentration of 3 • 10 - 5 M sublingually three times a day every other day 15 to 20 drops half an hour before meals, course treatment 30 days. The invention allows to increase the survival time of severe patients, to reduce the number of complications and relapses.
RU95100238A 1995-01-11 1995-01-11 Method of mamma cancer treatment RU2071771C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU95100238A RU2071771C1 (en) 1995-01-11 1995-01-11 Method of mamma cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU95100238A RU2071771C1 (en) 1995-01-11 1995-01-11 Method of mamma cancer treatment

Publications (2)

Publication Number Publication Date
RU2071771C1 RU2071771C1 (en) 1997-01-20
RU95100238A true RU95100238A (en) 1997-03-27

Family

ID=20163812

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95100238A RU2071771C1 (en) 1995-01-11 1995-01-11 Method of mamma cancer treatment

Country Status (1)

Country Link
RU (1) RU2071771C1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579857B1 (en) 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
RU2484539C1 (en) * 2011-12-21 2013-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Минздравсоцразвития России Method of treating malignant new growths in experiment

Also Published As

Publication number Publication date
RU2071771C1 (en) 1997-01-20

Similar Documents

Publication Publication Date Title
RU94038043A (en) Use of the substituted adenine derivatives for multiple sclerosis treatment
AU1256288A (en) Treatment of human viral infections by dsrna combined with viral inhibitors
DE69030880D1 (en) Composition for stimulating the immune system
RU94028670A (en) Immunopotentiating agents, methods of treatment of immunodeficient mammalian, viral infections and cancer in mammalian also
ATE322283T1 (en) TRANSDERMAL USE OF SECRETIN TO TREAT AUTISM
ATE73347T1 (en) ANTIVIRAL IMMUNOTHERAPEUTIC AGENT AND ITS PRODUCTION.
Verghese et al. A pertussis/choleratoxin-sensitive N protein may mediate chemoattractant receptor signal transduction
DK160429C (en) N-HETEROCYCLIC GLYCOSIDE WITH ANTITUMUM EFFECTS, PREPARATION THEREOF AND PHARMACEUTICAL PREPARATION CONTAINING THE GLYCOSIDE
ES8801580A1 (en) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
RU95100238A (en) Method of treatment of mamma cancer
NO893135D0 (en) PROCEDURE FOR THE PREPARATION OF N-2,3-BUTADIENYL TRI- AND TETRAAMINOALKANDER DERIVATIVES.
FR2632525B1 (en) THERAPEUTIC APPLICATION OF HUMAN MYELOPEROXYDASE
RU94045125A (en) Method of treatment of uterus and ovary cancer
ES8304152A1 (en) Aminocyclitol derivatives, their preparation and pharmaceutical preparations containing them.
DE3771057D1 (en) CYTOSTATIC ACTIVE SUBSTANCE CONTAINING PLATINUM.
Stone The possible role of mega-ascorbate in the endogenous synthesis of interferon
KR890017363A (en) Strobiliurin derivatives, their preparation and uses
RU94046312A (en) Use of biologically active ureido-derivatives for treatment lentivirus-induced disease, products containing ureido-derivatives
DE3650368T2 (en) Use of Depogen to treat restricted blood circulation.
SU1676628A1 (en) Non-alcoholic agent "glycal"
AU7714087A (en) Therapeutic treatment of intestinal inflammation by administration of 3,4-dihydro-2H-1-benzopyran derivatives
SU833247A1 (en) Method of treating diseases caused by tick bites
RU94036169A (en) Method for treating hepatitis
RU94016196A (en) Method for treating the cases of abdominal typhoid
RU94033173A (en) Method of enhanced reproductive function in men